Komori
Human Metabolome Technologies (6090) · InitiativeRaised

Development of New Markets Related to Foods with Function Claims and Other Areas

First written in FY2016-Q4. 5 of 9 entries say "Raised", first in FY2019. Latest entry: FY2026.

9entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016-Q4 – FY2017RaisedFY2019 – FY20262016: 220162017: 220172018: 020182019: 120192020: 020202021: 020212022: 020222023: 120232024: 120242025: 020252026: 22026
Same theme, other companies
Expansion into the functional foods and healthcare testing markets based on metabolomics analysisA theme 2 companies write about · 0 as a headwind · 3 as a tailwind

0 other companies' latest entry also says "Raised".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026RaisedAnnual report

    「In the fiscal year ending June 2027, our group will enter the business of contract healthcare testing services, outside the research and development field.」

    In addition to developing markets for functional materials, biomanufacturing and other areas, the Group indicated plans to enter the contract healthcare testing market outside the research and development field in the fiscal year ending June 2027.
  2. 2026-08-20RaisedFinancial results presentation

    「• Begin with private-pay medical testing using mass spectrometers (scheduled to start in January 2027) • Plan to add approximately 1 customer per year」

    Private-pay medical testing was specified as a new business area in addition to the existing healthcare and bio-manufacturing fields.
  3. FY2024RaisedAnnual report

    「The government has also announced Bioeconomy Strategy 2024, and the market for biomanufacturing, which contributes to reducing environmental impact, achieving a resource-independent circular economy and ensuring a stable food supply, among other objectives, is expected to expand rapidly. Some estimates put the bioeconomy market at ¥200 trillion to ¥400 trillion between 2030 and 2040, and the Bioeconomy Strategy sets a target of ¥100 trillion in 2030.」

    In addition to the conventional markets for functional-label foods and healthcare-related products, the Group explicitly identified biomanufacturing and the bioeconomy market as new areas for development and business opportunities.
  4. FY2023RaisedAnnual report

    「The healthcare-related market, including functional-label foods, is expanding as consumers become increasingly health-conscious.」

    The explanation has expanded from developing new markets related to functional-label foods and other areas to viewing the expansion of the healthcare-related market, including functional materials, as a business opportunity.
  5. FY2019RaisedAnnual report

    「The Group aims to increase sales by developing new markets in the food and chemical fields.」

    The target area has expanded from conventional markets related to functional-label foods and other areas to new-market development in the food and chemical fields.
  6. FY2017RestatedAnnual report

    「The Group focused on developing new markets, including those related to functional-label foods.」

    Continues to state that it is developing new markets, including those related to functional-label foods.
  7. FY2017-Q2RestatedAnnual report

    「In this business segment, the Group continued its active promotional activities from the previous fiscal year and worked to acquire large projects, while focusing on cultivating new markets, including those related to foods with function claims.」

    Continues to develop new markets, including those related to functional-label foods.
  8. FY2017-Q1RestatedAnnual report

    「The Group focused on developing new markets, including those related to functional-label foods.」

    Continues to state that it is developing new markets, including those related to functional-label foods.
  9. FY2016-Q4First statedAnnual report

    「The Group focused on developing new markets, including those related to functional-label foods.」

    It explicitly identified new-market development as a means of expanding the market for the metabolome analysis business.
Moved together

"Productivity Improvement in Analytical Work" moved the same way as this thread, in the same document, in 4 of its 9 moves.

444443★123456
  1. ★This thread
  2. 1Productivity Improvement in Analytical Work4×
  3. 2Development of a New Service in the Metabolome Analysis Business4×
  4. 3Capital investment to expand analytical capabilities and accelerate research and development4×
  5. 4Policy of prioritizing retained earnings and considering future dividends4×
  6. 5Healthcare Solutions Business: ¥100 million in sales and segment profitability in five years4×
  7. 6Proactive Talent Acquisition and Organizational Revitalization3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet. It last moved in the Financial results presentation of 2026-08-20: "Raised".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Development of New Markets Related to Foods with Function Claims and Other Areas | Human Metabolome Technologies,Inc. (6090) | Komori